Christopher Rohde
Fondatore presso Factor Bioscience, Inc.
Provenienza dei contatti di primo grado di Christopher Rohde
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA.
1
| Private Company | Miscellaneous Commercial Services | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Christopher Rohde tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder | |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Medical/Nursing Services | Founder | |
ETERNA THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Princeton University | College/University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Settori
Health Technology | 3 |
Health Services | 2 |
Finance | 2 |
Consumer Services | 2 |
Posizioni
Director/Board Member | 3 |
Founder | 3 |
Chief Executive Officer | 3 |
Corporate Secretary | 2 |
President | 2 |
Contatti più connessi
Insiders | |
---|---|
Matthew Angel | 6 |
- Borsa valori
- Insiders
- Christopher Rohde
- Connessioni Società